Compare NSPR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSPR | ACET |
|---|---|---|
| Founded | 2005 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.8M | 93.5M |
| IPO Year | N/A | N/A |
| Metric | NSPR | ACET |
|---|---|---|
| Price | $1.95 | $0.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.50 | ★ $8.50 |
| AVG Volume (30 Days) | 112.9K | ★ 1.9M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,779,000.00 | N/A |
| Revenue This Year | $22.76 | N/A |
| Revenue Next Year | $75.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.04 | N/A |
| 52 Week Low | $1.59 | $0.45 |
| 52 Week High | $3.80 | $1.11 |
| Indicator | NSPR | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 38.25 |
| Support Level | $1.74 | $0.50 |
| Resistance Level | $1.93 | $0.57 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 51.14 | 26.56 |
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.